The possible correlation between alterations in cytokinetic response to cisplatin (CP) treatment and drug resistance in human ovarian carcinoma cell lines was examined. Using dual parameter flow cytometry, we performed detailed time-course and dose-response analysis of cell cycle modifications in th
Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma
✍ Scribed by Sandra L. Jones; Ian D. Hickson; Adrian L. Harris; Paul R. Harnett
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- French
- Weight
- 678 KB
- Volume
- 59
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Human ovarian carcinoma exhibits a spectrum of responses to treatment with cisplatin, ranging from marked sensitivity to relative resistance. Variations in the efficiency with which cells repair cisplatin‐DNA adducts may in part determine cisplatin sensitivity. We have investigated the use of a novel cell‐free assay of nucleotide excision repair of platinated DNA to assess the DNA repair capacity of direct biopsies of untreated human ovarian carcinoma. In this pilot study, ovarian carcinoma extracts performed in vitro excision repair of platinated DNA. Moreover, tumors from different individuals varied as much as I O‐fold in their repair capacity in this assay. © 1994 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Extracts from HeLa S~3~ cells, human liver, and rat liver were found to contain an activity that transfers the methyl group from O^6^‐methyl‐guanine residues in DNA to a cysteine residue of an acceptor protein. The molecular weights of the acceptor proteins in HeLA cells and human liver